Close Menu

phase I clinical study

The companies will collaborate on a trial evaluating the HER3-targeted antibody drug conjugate patritumab deruxtecan in combiantion with AstraZeneca's Tagrisso.

The dose-finding study will now enroll up to 30 patients with sarcomas characterized by gene rearrangements similar to Ewing sarcoma.

The two companies will evaluate the efficacy of the combination in patients with ER-positive, HER2-negative, advanced breast cancer.

Chi-Med subsidiary Hutchison Medipharma has kicked off the Phase I trial in China and has dosed its first patient with the investigational IDH inhibitor.

The study will assess the maximum tolerated dose of the first-in-class drug, QBS10072S, for patients with a variety of metastatic cancers expressing LAT1 signatures.

The drug, designed to reactivate p53, will be evaluated in combination with chemotherapy and Venclexta as a frontline treatment for patients with TP53-mutant AML.

The Phase Ib/II trial will assess dosage and antitumor activity of MEN1611 plus Erbitux for patients with PIK3CA-mutated, RAS and RAF wildtype advanced colorectal cancer.

Researchers reported a correlation between ctDNA clearance and progression-free survival in EGFR-positive, MET-amplified patients treated with Tagrisso and savolitinib.

The firms will jointly study the combination, and Sanofi will have an exclusivity period to negotiate the in-licensing of KN026, contingent on certain milestones.

More than 40 percent of women with advanced mismatch repair-deficient endometrial cancer had an objective response to GSK's anti-PD-1 monoclonal antibody.